MediCool develops a non‑invasive, temperature‑based cardioversion system that terminates dangerous cardiac arrhythmias by applying controlled, localized cooling instead of painful electrical shocks. The technology integrates real‑time ECG feedback and safety algorithms, and is compatible with standard electrophysiology lab equipment for use in hospitals and emergency departments.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cardioversion procedures rely on high‑energy electrical shocks that cause significant patient discomfort, require sedation, and carry risks of tissue injury. These limitations reduce patient acceptance and can complicate treatment of life‑threatening arrhythmias such as atrial fibrillation or ventricular tachycardia.
Solution
MediCool is developing a non‑invasive, temperature‑based cardioversion technology—Cool Cardioversion—that terminates dangerous cardiac arrhythmias without delivering painful electrical shocks. The system applies controlled, localized cooling to cardiac tissue to interrupt abnormal electrical circuits, achieving rhythm restoration while minimizing pain and eliminating the need for deep sedation. Pre‑clinical studies and first‑in‑human cases have demonstrated feasibility and safety of the approach. The device is designed for use in hospital electrophysiology labs and emergency settings, offering clinicians a rapid, patient‑friendly alternative to conventional shock therapy. Ongoing prototype testing focuses on precise temperature control, real‑time cardiac monitoring, and integration with existing cardiac mapping systems.
Target Audience
Primary customers are hospitals, cardiac electrophysiology centers, and emergency departments that treat patients with atrial fibrillation, ventricular tachycardia, or other life‑threatening arrhythmias.
Features
- Controlled, localized cardiac cooling to achieve rhythm conversion without electrical shock
- Real‑time electrocardiographic feedback to monitor arrhythmia termination and tissue temperature
- Integrated safety algorithms that limit cooling depth and duration to prevent tissue damage
- Compatibility with standard electrophysiology lab equipment and monitoring platforms
- Portable, single‑use catheter or surface applicator designed for rapid deployment in acute care settings